Keying Han

Keying Han

Auto-generated profile, based on publicly available information

Keying Han

Gut Health Research Center,Mom's Garden Institute of Nutrition and Health, Saarbrücken, Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2022 in Food Hydrocolloids
Verified
Journal Article
Closed access
KHKeying Han
Keying Han
SLShanshan Li
Shanshan Li
YYYuling Yang
Yuling Yang
XFXiao Feng
Xiao Feng
XTXiaozhi Tang
Xiaozhi Tang
YCYumin Chen
Yumin Chen

5 May 2021 in International Journal of Food Science and Technology
Verified
Journal Article
Closed access
PDF file
KHKeying Han
Keying Han
XFXiao Feng
Xiao Feng
YYYuling Yang
Yuling Yang
SWSumeng Wei
Sumeng Wei
XTXiaozhi Tang
Xiaozhi Tang
YCYumin Chen
Yumin Chen

9 October 2026 in World Journal of Public Health
Verified
Journal Article
Open access
PDF file
ALAmy Li
Amy Li
KHKeying Han
Keying Han
QLQidong Lu
Qidong Lu
JLJing Li
Jing Li
KYKaiye Yang
Kaiye Yang
JPJie Peng
Jie Peng
Background: Functional constipation impairs gut health and quality of life. Okra (Abelmoschus esculentus), traditionally used for treating gastrointestinal complaints, is rich in soluble dietary fiber and mucilaginous polysaccharides thought to increase stool water retention, soften feces, and promote luminal bulk, thereby facilitating colonic transit. Preclinical studies link okra mucilage to gut barrier support and favorable shifts in gut microbiota composition. The eLAX TM Probiotic-Botanical Supplement (eLAX) combines okra extract with Lactobacillus casei probiotics. We evaluated its efficacy and safety in a single-center, open-label, self-controlled study and report the complete 12-week dataset. Methods: Fifty-one adults meeting Rome IV criteria for functional constipation were enrolled at Xiangya Hospital; 49 completed the study and were analyzed. Participants received descending doses of eLAX over 10 weeks with intervening washouts (Weeks 1-2: 4 tablets/day; Week 3 washout; Weeks 4-6: 3/day; Week 7 washout; Weeks 8-10: 2/day), then 2 weeks of observation without product. The primary endpoint was the responder rate (increase in spontaneous bowel movements [SBMs] per 24 h versus baseline) at Weeks 2, 6, 10, and 12. Exploratory endpoints included gut microbiota, PAC-SYM, PAC-QOL-12, bowel diaries (frequency, straining, Bristol Stool Scale [BSS], abdominal pain), and assisted-defecation use. Safety included laboratory tests and colonoscopy in a subset. Results: Responder rates (N=49) were 87.8%, 61.2%, 55.1%, and 42.9% at Weeks 2, 6, 10, and 12. Mean SBM frequency rose from 0.51/day at baseline to 1.88, 1.35, and 1.12/day at Weeks 2, 6, and 10 (all p <0.0001), remaining above baseline at Week 12 (0.82/day, p =0.0086). Mean time to first bowel movement was 5.88±4.12 h (61.2% within half a day). BSS shifted from types 1-2 toward types 3-7 after 10 weeks (mean +2 grades); 69.3% retained ideal types 3-4 at Week 12. Straining resolved by Week 10; incomplete evacuation and abdominal pain declined. PAC-SYM (0-30) fell from 15.96±3.33 to 1.00±1.98 at Week 10 (−93.73%, p <0.0001) and remained improved at Week 12 (−78.64%). PAC-QOL-12 improved by 88.76% at Week 10 ( p <0.0001). Microbiota diversity rose 9.65% ( p =0.0091) and the Bacteroidetes/Firmicutes ratio rose 162.57% ( p <0.0001) at Week 10. No product-related adverse events occurred; colonoscopy (n=10) showed no melanosis coli. Conclusion: Over 12 weeks, eLAX was associated with significant improvements in bowel frequency, stool consistency, symptoms, quality of life, and gut microbiota, with a favorable safety profile. Benefits were most durable in participants without baseline spontaneous defecation; milder cases may need longer low-dose maintenance after tapering.